Patient experience with darifenacin – results of a short-term community-based survey in managing overactive bladder

References

• Stewart W, Herzog R, Wein A, et al. Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001;20:406-8
   Google Scholar
• Onukwugha E, Zuckerman IH, McNally D, et al. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 2009;15:S90-S97
   PubMedGoogle Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002;187:116-26
   PubMed Web of Science ®Google Scholar
• Garnett S, Swithinbank L, Ellis-Jones J, et al. The long-term natural history of overactive bladder symptoms due to idiopathic detrusor overactivity in women. BJU Int 2009;104:948-53
   PubMed Web of Science ®Google Scholar
• Gray M. Incontinence-related skin damage: essential knowledge. Ostomy Wound Manage 2007;53:28-32
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures. J Am Geriatr Soc 2000;48:721-5
   PubMed Web of Science ®Google Scholar
• Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003;92:948-54
   PubMed Web of Science ®Google Scholar
• Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 2001;23:1245-59
   PubMed Web of Science ®Google Scholar
• Nicolson P, Kopp Z, Chapple CR, et al. It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol 2008;13:343-59
   PubMed Web of Science ®Google Scholar
• Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol 2010;57:586-91
   PubMed Web of Science ®Google Scholar
• Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010;75:526-32
   PubMed Web of Science ®Google Scholar
• Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006;50:1050-7
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Chapple CR, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001
   PubMed Web of Science ®Google Scholar
• Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005;95:580-6
   PubMed Web of Science ®Google Scholar
• Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006;98:1025-32
   PubMed Web of Science ®Google Scholar
• Donovan A, Bosch R, Gotoh M, et al. Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A (eds). Incontinence. Book 1. Basics and evaluation. International Continence Society, 2005
   Google Scholar
• Abrams P, Huels J, Kelleher C. Clinical relevance of quality of life data with darifenacin in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2005;16:S101
   Google Scholar
• Weaver M, Patrick DL, Markson LE, et al. Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997;3:579-94
   PubMed Web of Science ®Google Scholar
• McCracken LM, Klock PA, Mingay DJ, et al. Assessment of satisfaction with treatment for chronic pain. J Pain Symptom Manage 1997;14:292-9
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6
   PubMed Web of Science ®Google Scholar
• Schabert VF, Bavendam T, Goldberg EL, et al. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 2009;15:S118-S122
   PubMedGoogle Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Zinner N, Kobashi K, Koochaki P, et al. Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument. Neurourol Urodyn 2010; in press. doi: 10.1002/nau.20890
   Google Scholar
• Cohen SJ, Robinson D, Dugan E, et al. Communication between older adults and their physicians about urinary incontinence. J Gerontol A Biol Sci Med Sci 1999;54:M34-M37
   Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276-82
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 2007;23:65-76
   PubMed Web of Science ®Google Scholar
• Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006;68:29-37
   PubMed Web of Science ®Google Scholar
• Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-7
   PubMed Web of Science ®Google Scholar
• Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006;97:540-6
   PubMed Web of Science ®Google Scholar
• Sussman DO, Kraus SR, Carlsson M, et al. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007;23:777-81
   PubMed Web of Science ®Google Scholar
• Khullar V, Foote J, Larson-Peters A, et al. Darifenacin effectively relieved overactive bladder symptoms as early as 6–8 days of initiating treatment. ICS/IUGA Toronto, Canada, August 23–27, 2010;Abstract 620
   Google Scholar
• FDA Report. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2006. Available at: http://www.fda.gov/ohrms/dockets/dockets/06d0044/06D-0044-EC30-Attach-1.pdf [Last accessed: 21 July 2010]
   Google Scholar